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Hypotension Due to Kir6.1 Gain-of-Function in Vascular Smooth
Muscle
Anlong Li, MD, PhD; Russell H. Knutsen, BS; Haixia Zhang, MD, PhD; Patrick Osei-Owusu, PhD; Alex Moreno-Dominguez, PhD;
Theresa M. Harter, BS; Keita Uchida, BS; Maria S. Remedi, PhD; Hans H. Dietrich, PhD; Carlos Bernal-Mizrachi, MD;
Kendall J. Blumer, PhD; Robert P. Mecham, PhD; Joseph C. Koster, PhD;† Colin G. Nichols, PhD
Background-—KATP channels, assembled from pore-forming (Kir6.1 or Kir6.2) and regulatory (SUR1 or SUR2) subunits, link
metabolism to excitability. Loss of Kir6.2 results in hypoglycemia and hyperinsulinemia, whereas loss of Kir6.1 causes Prinzmetal
angina–like symptoms in mice. Conversely, overactivity of Kir6.2 induces neonatal diabetes in mice and humans, but
consequences of Kir6.1 overactivity are unknown.
Methods and Results-—We generated transgenic mice expressing wild-type (WT), ATP-insensitive Kir6.1 [Gly343Asp] (GD), and
ATP-insensitive Kir6.1 [Gly343Asp,Gln53Arg] (GD-QR) subunits, under Cre-recombinase control. Expression was induced in smooth
muscle cells by crossing with smooth muscle myosin heavy chain promoter–driven tamoxifen-inducible Cre-recombinase
(SMMHC-Cre-ER) mice. Three weeks after tamoxifen induction, we assessed blood pressure in anesthetized and conscious animals,
as well as contractility of mesenteric artery smooth muscle and KATP currents in isolated mesenteric artery myocytes. Both systolic
and diastolic blood pressures were signiﬁcantly reduced in GD and GD-QR mice but normal in mice expressing the WT transgene
and elevated in Kir6.1 knockout mice as well as in mice expressing dominant-negative Kir6.1 [AAA] in smooth muscle. Contractile
response of isolated GD-QR mesenteric arteries was blunted relative to WT controls, but nitroprusside relaxation was unaffected.
Basal KATP conductance and pinacidil-activated conductance were elevated in GD but not in WT myocytes.
Conclusions-—KATP overactivity in vascular muscle can lead directly to reduced vascular contractility and lower blood pressure. We
predict that gain of vascular KATP function in humans would lead to a chronic vasodilatory phenotype, as indeed has recently been
demonstrated in Cantu syndrome. ( J Am Heart Assoc. 2013;2:e000365 doi: 10.1161/JAHA.113.000365)
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K ATP channels were ﬁrst reported in cardiac myocytes
1
and subsequently identiﬁed in pancreatic b cells,
skeletal muscle, vascular smooth muscle (VSM),2,3 and the
central nervous system. KATP channels act as metabolic
molecular sensors, being inhibited by ATP, and activated by
MgADP.4 Two inward rectiﬁer potassium channel (Kir) genes,
Kir6.1 (KCNJ8) and Kir6.2 (KCNJ11), encode the pore-forming
subunits of the KATP channel, and 2 ATP-binding cassette
(ABC) genes, SUR1 (ABCC8) and SUR2 (ABCC9), encode
obligate regulatory subunits. The Kir6 proteins exhibit distinct
nucleotide sensitivities5 as well as distinct but overlapping
tissue distributions.6 Kir6.2 generates KATP channels in
striated muscle, pancreas, and certain neuronal tissues,
whereas Kir6.1 predominantly generates channels in VSM
cells (VSMCs) and endothelial cells.
In the pancreatic b cell, KATP channels represent the central
link betweenmetabolism and the triggering of insulin secretion.
Loss-of-function (LOF) mutations of Kir6.2 (or SUR1) results in
congenital hyperinsulinism in humans, and essential features
are replicated in Kir6.2 (or SUR1) knockout7 or domi-
nant-negative transgenic8 mice. Conversely, Kir6.2 (or SUR1)
gain-of-function (GOF) mutations underlie neonatal diabetes,9
and the human disease was actually predicted by studies of
Kir6.2 GOF transgenic mice.10 Less is known about the disease
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relevance of Kir6.1. The only animal models of genetically
modiﬁed Kir6.1 are the Kir6.1 knockout (Kir6.1/) mouse11
and the partial LOF (dominant-negative) Cx1-Kir6.1[AAA]
mouse.12 These animals implicate a role of Kir6.1 and the
partner SUR2B subunit in the vascular system, speciﬁcally in
control of coronary artery contractility and systemic blood
pressure, and these mice, together with SUR2 knockout
animals, reiterate a Prinzmetal angina and hypertensive
phenotype,11–13 explainable by loss of KATP somewhere within
the vascular system. There are also several reports that cardiac
early repolarization syndrome (ERS) is associated with Kir6.1
gene variants that may generate GOF channels,14–16 although
the relevant location of Kir6.1 in this case is unknown.
To date, there is no animal model available in which to
further probe the potential in vivo role of Kir6.1 GOF. Given
the high sequence homology between Kir6.1 and Kir6.2, we
hypothesized that GOF mutations homologous to those in
Kir6.2 that cause neonatal diabetes would have parallel
pathological effects if present in Kir6.1. To address this, we
have engineered mutations in Kir6.1 homologous to those
that cause GOF in Kir6.2 and then generated novel Kir6.1 GOF
transgenic mice that express these constructs as well as
wild-type (WT) constructs under tamoxifen-inducible
Cre-recombinase control. These mice permit the selective
induction of transgene expression in any tissue of interest,
thereby modeling tissue-speciﬁc expression of mutations. By
crossing with SMMHC-Cre-ER) mice,17 we have targeted the
transgene to smooth muscle cells. Within 3 weeks after
tamoxifen injection, both ATP-insensitive Kir6.1 [Gly343Asp]
(GD)/Cre double-transgenic (DTG) and ATP-insensitive Kir6.1
[Gly343Asp, Gln53Arg] (GD-QR)/Cre DTG mutation mice
develop a signiﬁcant hypotensive phenotype, as a result of
enhanced K+ conductance and reduced contractility in VSM.
In contrast, both blood pressure and K+ conductance are
unaffected in WT/Cre DTG animals, whereas blood pressure
was elevated in Kir6.1[AAA]/Cre DTG and Kir6.1/ animals.
The results have important implications for understanding the
consequence of Kir6.1 channel GOF in vivo and provide
important hints for exploring the genetic and translational
relevance in humans, providing a potential model for human
Cantu syndrome, a multiorgan disease now shown to result
from SUR2 GOF mutations.
Materials and Methods
Mutation and Expression of KATP Channels in
COSm6 Cells
Point mutations ([Gly343Asp], [Gln53Arg]) were prepared
using the Stratagene Quickchange kit, in rat Kir6.1 cDNA.
COSm6 cells were transfected with pCDNA3-Kir6.1 (Kir6.1
WT, Kir6.1 [Gly343Asp], Kir6.1 [Gln53Arg]), pcDNA3-SUR1,
and green ﬂuorescent protein using FuGENE 6 Transfection
Reagent (Promega). After transfection, cells were cultured for
48 hours, and excised patch-clamp experiments were made
at room temperature using a perfusion chamber that allowed
for the rapid switching of solutions. Data were typically
ﬁltered at 1 kHz, digitized at 5 kHz, and stored directly on a
computer hard drive using Clampex software (Molecular
Devices). The standard pipette (extracellular) and bath
(cytoplasmic) solution used in these experiments had the
following composition (in mmol/L): KCl 140, EGTA 1, K2-EDTA 1,
and K2HPO4 4, pH 7.3.
86Rubidium Efﬂux
86Rb+ efﬂuxwas used to assay transport through KATP channels.
COSm6 cells were grown and transfected in 12-well plates.
Twenty-four hours after transfection, cells were incubated
overnight at 37°C in DMEM containing 86RbCl 0.05 MBq/mL.
The medium was then aspirated and incubated cells were
washed 39 with Ringer’s solution (in mmol/L: HEPES 10, NaCl
118, NaHCO3 25, KCl 4.7, KH2PO4 1.2, CaCl2 2.5, MgSO4 1.2,
adjusted to pH 7.4 with NaOH), and incubated for 15 minutes
with 1 mL of Ringer’s solution with or without metabolic
inhibitors, Oligomycin 2.5 mg/mL and 2-deoxy-D-glucose
1 mmol/L at room temperature. After incubation, the super-
natant was aspirated into vials, scintillation ﬂuid was added for
counting (4 mL to each vial), and new Ringer’s solution was
immediately added to the well. This step was repeated to time
points 2.5, 5, 7.5, 15, 25, and 40 minutes, and 2% SDS was
added to lyse the cells, which were assayed for remaining Rb
content. Radioactivity in the supernatant and cell lysates was
counted and efﬂux was expressed as a percentage of the total
amount of radioactivity initially loaded into the cells.
Generation of CX1-Kir6.1 WT, GD, and GD-QR
Transgenic Mice
All procedures complied with the standards for the care and
use of animal subjects as stated in the “Guide for the Care
and Use of Laboratory Animals” (National Institutes of Health,
revised 2011) and were reviewed and approved by the
Washington University Animal Care and Use Committee. Rat
and mouse Kir6.1 differ in only 2 amino acids (of 424), and
inducible Kir6.1 transgenes were generated by subcloning rat
WT Kir6.1 as well as Kir6.1[Gly343Asp] and Kir6.1[Gly343Asp,
Gln53Arg] cDNAs downstream of the CX-1 promoter in the
pBS-CX1-LEL vector (a gift from Dr Gary Owens, University of
Virginia), which contains the chicken b-actin (CX1) promoter
followed by the enhanced green ﬂuorescent protein coding
region (including a stop codon), ﬂanked by 2 loxP sites, to
create CX1-Kir6.1, CX1-Kir6.1[Gly343Asp], and CX1-Kir6.1
[Gly343Asp,Gln53Arg] transgenic constructs. The expression
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cassette was excised by enzyme digestion, puriﬁed, and
microinjected into fertilized eggs of C57Bl6xCBA mice,
according to standard techniques, in the Washington Univer-
sity Neuroscience Transgenic Facility. Transgenic mice were
identiﬁed by the use of PCR on mouse-tail DNA using green
ﬂuorescent protein–speciﬁc oligonucleotide primers. Six to 11
founder mice carrying WT, GD, or GD-QR were identiﬁed and
bred to homogeneity by multiple (69) back-crossing to
C57Bl6 mates. Of the founder mice that were generated, the
lines with highest expression were WT line 1 and line 2, GD
line 9 and line 10, and GD-QR line 1 and line 2. Accordingly,
analysis was concentrated on these high-expressing animals,
and all presented data are from these animals.
Blood Pressure Measurements
In Anesthetized Animals
Animals were anesthetized using inhaled isoﬂurane and
restrained on a heated holder to maintain body temperature.
A Millar pressure transducer was carefully inserted into the
right carotid artery and moved to the ascending aorta, where
baseline heart rate, systolic, diastolic, and mean blood
pressures were monitored. All measurements were obtained
under 1% isoﬂurane anesthesia. Systolic, diastolic, and mean
blood pressures and heart rate were calculated using Chart 5
for Windows software.
In Conscious Animals
Systolic blood pressure, diastolic blood pressure, and mean
blood pressure were also measured in conscious mice using a
tail-cuff system (Kent Scientiﬁc) as previously described.18
Animals were acclimated to handling and placement in the
apparatus daily for 2 weeks before the measurement of blood
pressure. Multiple measurements were made at each of 3
daily sessions and averaged to obtain a single value for each
mouse.
Tissue Preparation and Smooth Muscle Cell
Isolation
Adult mice were anesthetized with Avertin (Sigma-Aldrich),
and aortas and mesenteric arteries were rapidly removed and
placed in ice-cold HEPES-buffered PSS containing (in mmol/L)
NaCl 134, KCl 6, CaCl2 2, MgCl2 1, HEPES 10, and glucose 10,
with pH adjusted to 7.4 with NaOH. For molecular biology
experiments, the mesenteric arteries and the aortas were
dissected, cleaned to remove adventitial connective tissue,
and were kept in a 80°C freezer until use. For patch-clamp
experiments, individual smooth muscle cells were enzymati-
cally dissociated from mesenteric arteries in isolation solution
of the following composition (in mmol/L): NaCl 55, sodium
glutamate 80, KCl 5.6, MgCl2 2, HEPES 10, and glucose 10,
pH 7.3 with NaOH, and then placed into isolation solution
containing papain 12.5 lg/mL, dithioerythreitol 1 mg/mL,
and BSA 1 mg/mL for 10 minutes (at 37°C), and then
immediately transferred to isolation solution containing
collagenase (type H:F=1:2) 1 mg/mL, CaCl2 100 lmol/L,
and BSA 1 mg/mL for 8 minutes (at 37°C). Arteries were
subsequently washed in ice-cold isolation solution for
10 minutes and triturated using a polished glass Pasteur
pipette to yield single smooth muscle cells. Cells were stored
on ice and used for electrophysiology experiments between 1
and 8 hours after isolation. For primary culture of VSMCs, the
procedures were as follows: Arteries were isolated and
cleaned free of connective tissue. The endothelium was
removed by gently rubbing the luminal surface with a cotton
swab. Arteries were then digested as just described—for step
1, aorta for 30 minutes and mesenteric artery for 20 minutes,
and for step 2, aorta for 10 minutes and mesenteric artery for
7 minutes. Smooth muscle cells were gently dispersed via
trituration with a small-bore pipette in Ca2+-free HBSS at room
temperature. The dispersed cells were cultured at 37°C and
5% CO2 in DMEM/F-12 medium (with L-glutamine) supple-
mented with 10% fetal bovine serum, streptomycin 100 U/mL,
and penicillin 0.1 mg/mL for 3 to 5 days before use.
Whole-Cell Patch-Clamp Electrophysiology
Freshly isolated mesenteric artery smooth muscle cells were
allowed to adhere to a glass coverslip in the bottom of the
recording chamber for 10 minutes before experimentation.
KATP currents were measured using the whole-cell conﬁgura-
tion of the patch-clamp technique with an Axopatch 700B
ampliﬁer (Molecular Devices) at holding potential 70 mV.
The bath solution was HEPES-buffered PSS containing (in
mmol/L) KCl 140 (or KCl 6 plus NaCl 136), CaCl2 2, MgCl2 1,
HEPES 10, and glucose 10, with pH adjusted to 7.4 with KOH
(or NaOH). The pipette solution contained (in mmol/L)
potassium aspartate 110, KCl 30, NaCl 10, MgCl2 1, HEPES
10, CaCl2 0.5, K2HPO4 4, and EGTA 5, with pH adjusted to 7.2
with KOH. Membrane currents were ﬁltered at 1 kHz and
digitized at 4 kHz.
Total RNA Extraction, cDNA Synthesis, and
Quantitative Real-Time PCR
Arteries were mechanically homogenized, and total RNA was
extracted using a commercial kit (Qiagen). After removal of
contaminating DNA (Qiagen), RNA content was determined by
NanoDrop 1000 (Thermo Scientiﬁc). Total RNA (0.5 lg) was
used for ﬁrst-strand cDNA synthesis with random primers and
Superscript III RNase H reverse transcriptase (Invitrogen)
according to the manufacturer’s protocol. Primers for PCR
DOI: 10.1161/JAHA.113.000365 Journal of the American Heart Association 3
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were designed to regions speciﬁc for rat Kir6.1 by primer 3
online software (sense: TGTGACCAATGTCAGGTCATTCACTTC;
antisense: TGATGATCAGACCCACAATGTTCTGC); b-actin con-
trol primers were obtained from Sigma. At least 1 of each
primer pair was designed to span exon–exon junctions, to
minimize the possibility of amplifying genomic DNA. RT-PCR
was carried out for 30 cycles using PlatinumTaq DNA
polymerase (Invitrogen), which involved denaturation at
94°C for 30 seconds, annealing at 55°C for 45 seconds,
and extension at 72°C for 90 seconds, followed by a ﬁnal
extension at 72°C for 10 minutes, and the products were then
stored at 4°C. PCR products were analyzed by electrophoresis
with 1.8% agarose gel and visualized by ethidium bromide
staining to optimize the primer for real-time PCR. Real-time
PCRs were detected by use of SYBR Green and were
performed with ABI Prism 7000 (Applied Biosystems), using
1 lL of cDNA as template in each 20-lL reaction mixture. The
PCR protocol consisted of initial enzyme activation at 95°C for
5 minutes, followed by 40 cycles at 95°C for 15 seconds, and
at 60°C for 1 minute. To conﬁrm the speciﬁcity of PCR
products, we obtained a melting curve at the end of each run
by slow heating with increments of 0.5°C/10 seconds from
60° to 95°C, with ﬂuorescence detected at intervals of 0.5°C.
Standard gel electrophoresis was also performed to ensure
the end product generated a single band with the predicted
size (100 to 150 bases). Following baseline correction, a
ﬂuorescence threshold was established and the cycle when
this threshold was crossed (Ct) was determined for each
reaction. To control for variability in RNA quantity, the
normalized value, DCt, for each sample was calculated by
using the formula DCt=Ct(actin)Ct(kir6.1). Relative expression
in TG tissue (normalized to WT) was then determined using the
following relationship: relative gene expression=2DDCt,
where DDCt=DCt (WT)DCt (TG).
Vessel Contractility and Reactivity
Measurements
Male mice were anesthetized with ketamine (87 mg/kg IP)
and xylazine (13 mg/kg IP). The small intestine was accessed
after the abdomen was shaved and a midline incision was
made, ﬁrst through the skin and then through the abdominal
muscle. The entire intestine was excised and placed in chilled
1% albumin in PSS (MOPS, pH 7.4) containing (in mmol/L)
NaCl 144, KCl 3.0, CaCl2 2.5, MgSO4 1.5, pyruvate 2.0,
glucose 5.0, EDTA 0.02, and NaH2PO4 1.21. The mouse was
then killed via cervical dislocation. With use of a pair of ﬁne
forceps and with the aid of a dissecting microscope, adipose
tissue was carefully removed from second order mesenteric
arteries. Sections of isolated vessels 2 to 3 mm in length
were excised and immediately placed in an organ chamber for
mounting onto glass pipettes.
An excised piece of mesenteric artery was transferred into
the organ chamber (2.5 mL vol) containing MOPS and
mounted on the stage of an inverted microscope (Zeiss
Axiovert S100TV). The vessel was cannulated on one end with
a glass perfusion pipette and occluded on the other end with a
collecting pipette such that no luminal ﬂow was allowed
during the experiment, and the lumen of the vessel ﬁlled with
1% albumin in MOPS buffer. The vessel was observed with a
video camera system (MTI CCD-72) to track and record
changes in vessel diameter in response to vasoactive agents.
Baseline internal diameter of the vessel was measured online
at 60 mm Hg and 37°C, with a computerized diameter
tracking system (sampling rate of 10 Hz, Diamtrak 3 Plus;
Montech Pty, Ltd). Vessel diameter in the presence of various
vasoactive agents was measured after at least 30 minutes’
equilibration, when the bath solution was replaced with
warmed MOPS buffer containing freshly prepared solution.
For vessel reactivity assays, excised pieces of mesenteric
artery were transferred and cannulated under no-ﬂow condi-
tion in an organ bath. After vessels were equilibrated for
30 minutes, the bath solution was replaced with warmed
MOPS containing increasing concentrations of phenylephrine
(PE), and changes in vessel diameter were continuously
recorded. To determine the effects of KATP channel blockade
on PE-induced vasoconstriction, cannulated vessels were
further incubated with glibenclamide 10 lmol/L for 10 min-
utes before performing dose-response experimentd with PE as
described. For KATP channel activation, PE dose-response was
assessed in the presence of pinacidil 100 lmol/L. For
vasodilatation experiments, vessels were constricted with
PE 5 lmol/L after 30 minutes of equilibration at 37°C. After
constriction had reached steady state (>1 minute), the bath
solution was changed to MOPS containing PE 5 lmol/L and
the endothelium-independent vasodilator sodium nitroprus-
side at various concentrations (109 to 104 mmol/L). After
the highest sodium nitroprusside concentration was applied,
the bath solution was replaced with MOPS to allow complete
vessel relaxation back to control values.
Statistical Analysis
Unless otherwise stated, values are given as meanSE; n
values refer to the number of events analyzed. Student’s t
tests were used for comparison of unpaired data. For
comparison between multiple data sets, we applied 1-way
ANOVA followed by post-hoc Tukey’s test or 2-way ANOVA
followed by Bonferroni’s posttests. When the sample size was
≤3, statistical analysis was not performed and signiﬁcance is
not assigned. Unless stated otherwise, asterisks in ﬁgures
indicate signiﬁcant difference (*P<0.05, **P<0.01) between
the test group and the control group within time point or
condition; nonsigniﬁcant differences are not indicated.
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Chemicals
Papain was purchased from Worthington Biochemical. Unless
otherwise stated, all other chemicals were obtained from
Sigma Chemical.
Results
Predicted Kir6.1 GOF Mutations Reduce Channel
ATP Sensitivity and Enhance Channel Activity in
Intact Cells
Kir6.1 has high homology to Kir6.2, and most Kir6.2
mutations identiﬁed as causal in neonatal diabetes are at
conserved residues. We generated Kir6.1[Gln53Arg] (Q53R,
QR) and Kir6.1[Gly343Asp] (G343D, GD) single mutants
(Figure 1A, equivalent to diabetes-causing Kir6.2 GOF muta-
tions Gly334Asp19 and Gln52Arg20), as well as Kir6.1[G343D,
Q53R] (GD-QR) double mutants, and examined channel
activity of these constructs in recombinant expression with
sulfonylurea receptor subunits. In contrast to Kir6.2, Kir6.1
channels require the presence of Mg-nucleotides for signif-
icant channel activity, even though channels are sensitive to
inhibition by ATP (Figure 1B), resulting in a biphasic depen-
dence of channel activity on MgATP.5 As shown in Figure 1B,
WT Kir6.1 channels are stimulated up to 1 mmol/L MgATP
and strongly inhibited at 10 mmol/L. In contrast, MgUDP
stimulates channels but has no inhibitory effect (Figure 1B).
Each of the mutant channels is activated similar to WT, but
each shows reduced inhibition by MgATP, and there is an
approximately additive effect in the GD-QR double mutant
(Figure 1C). Reduced sensitivity to ATP inhibition is expected
to result in enhanced channel activity in intact cells, and this
is conﬁrmed by 86Rb+ ﬂux experiments on intact cells, which
show larger 86Rb+ ﬂuxes from intact cells expressing
Figure 1. Reiteration of GOF phenotype from mutations in Kir6.1. A, Homology model of kir6.1 indicating location of mutated residues. Residue
Gly343 is found in the predicted ATP binding site, whereas Gln53 is located in the amino-terminus and is involved in transduction. B, Excised
patch currents from SUR1/Kir6.1 subunits coexpressed in COSm6 cells, in nucleotide-free Kint solution or in Mg-nucleotides as indicated. WT
channels are activated at low [ATP] and high [UTP]. WT channels become strongly inhibited at high (10 mmol/L) ATP, but Gln53Arg (Q53R) and
Gly343Asp (G343D) are insensitive to ATP inhibition. C, Averaged data from experiments as in (B) (currents in 10 mmol/L MgATP/current in
5 mmol/L MgUTP, meanSEM, n as indicated, 1-way ANOVA followed by post-hoc Tukey’s test). D, Representative data from an 86Rb efﬂux
experiment on untransfected (Unt) COS-m6 cells and cells transfected with Kir6.1WT, (G343D) or G343D, Q53R mutant channels, plus SUR1.
Basal activity of GD or GD-QR channels was signiﬁcantly higher than WT in the intact cell. GOF indicates gain-of-function; WT, wild-type.
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[Gly343Asp] and [Gly343Asp, Gln53Arg] mutants than cells
expressing WT channels, under basal conditions (Figure 1D).
Expression of Kir6.1 GOF in Smooth Muscle Cells
In order to study the effects of Kir6.1 GOF in vivo, we have
generated transgenic mice that express WT, GD, or GD-QR
mutant Kir6.1 constructs under tamoxifen-inducible
Cre-recombinase control in the pBS-CX1-LEL vector. The
transgenic animals express green ﬂuorescent protein ubiqui-
tously (Figure 2A), unless Cre-recombinase is expressed. By
crossing with smooth muscle myosin heavy chain promoter–
driven tamoxifen-inducible Cre-recombinase (SMMHC-Cre-ER)
mice,17 we speciﬁcally targeted the transgene to smooth
muscle cells. All single-transgenic (STG) mice and Kir6.1 WT,
GD, or GD-QR9SM-MHC-Cre double-transgenic (DTG) mice
were viable and showed no obvious anatomical or behavioral
pathology. Confocal images (Figure 2B) of cultured mesenteric
artery smooth muscle cells isolated 3 weeks after induction
show that the majority of myocytes from GD or GD-QR9Cre
DTG mice lose green ﬂuorescence but remain green in GD
or GD-QR STG) mice (Figure 2B). Real-time PCR analysis
(Figure 2C) shows that Kir6.1 mRNA level is signiﬁcantly
increased 12.64.5-fold in GD9SM-MHC-Cre DTG myocytes,
and 7.51.8-fold in myocytes from GD-QR9SM-MHC-Cre DTG
mice, compared with their STG littermates.
Kir6.1 GOF and LOF Transgenes Lead to Lower or
Higher Blood Pressure, Respectively
Baseline heart rate and systolic, diastolic, and mean blood
pressures were measured in anesthetized DTG and STG or WT
littermates, 3 weeks following tamoxifen induction in smooth
muscle. Both systolic and diastolic blood pressures were
signiﬁcantly lower in GD or GD-QR DTG compared with STG
littermates (Figure 3A through 3C) but, importantly, blood
pressure was not signiﬁcantly affected in WT DTG compared
with STG littermates (Figure 3D). Previous studies showed
that total loss of Kir6.1 (or SUR2) function induced a
Prinzmetal angina–like phenotype,11,12 and although an ele-
vated mean blood pressure was reported for the SUR2/
animals, there was no report of overt hypertension in Kir6.1/
animals. As additional controls for the present experiments, we
also measured blood pressure from Kir6.1/ mice11 and from
dominant-negative LOF Kir6.1[AAA] mice12 crossed with
SMMHC-Cre mice to target the transgene to the smooth
muscle cells. Interestingly, blood pressure from both Kir6.1/
and Kir6.1[AAA]9Cre-DTG mice was signiﬁcantly higher than
that of control WT or STG littermates (Figure 3E and 3F). As
summarized in Figure 3G, this collection of mice represent a
continuum of mean blood pressures ranging from <90% of
control in GOF animals to >110% of control in LOF animals.
Heart rates were not signiﬁcantly different between groups,
Figure 2. Generation of Cx1-Kir6.1[WT, GD, and GD-QR] transgenic
mice, and targeted transgene expression in speciﬁc tissue. A, CX1
mice crossed with C57 WT mice, under UV light, newborn mice
carrying the CX1 transgene were green (*), whereas nontransgenic
mice were dark. B, Primary cultured mesenteric artery smooth
muscle cells from the GD and GD-QR DTG offspring of CX1
transgenic mice and SMMHC-Cre-ER mice. Confocal images show
that VSM cells from DTG with tamoxifen-induction lose green
ﬂuorescence but other cells remain green. C, In transgene targeted
vascular tissue, quantitative real time PCR shows the copy number of
transgene in DTG mice is signiﬁcantly higher than that of their STG
littermates. DTG indicates double-transgenic; PCR, polymerase chain
reaction; SMMHC-Cre-ER, smooth muscle myosin heavy chain
promoter-driven tamoxifen inducible Cre recombinase; STG,
single-transgenic; VSM, vascular smooth muscle.
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although we cannot exclude the possibility that insufﬁcient
sample size might mask small changes. As discussed earlier,
transgenes were expressed at 10-fold higher levels than
endogenous, at the mRNA level. Given the requisite stoichi-
ometry between Kir6 and SUR subunits to generate functional
KATP channels,
21 we expect that the net effect will be
replacement of endogenous subunits with transgenic subunits
in the surface channels, but we did not measure endogenous
Kir6 or SUR mRNA or protein levels and cannot exclude the
possibility that these may change. We also cannot know
Figure 3. Kir6.1 GOF results in hypotension in mice, whereas Kir6.1 LOF results in hypertensive phenotype. A, Typical blood pressure
measurement traces show that both systolic and diastolic blood pressure are markedly lower in anesthetized mice expressing GD-QR in smooth
muscle cells than that of control littermates. B through F, Averaged systolic, diastolic, and mean blood pressures from each genotype studied in
GD-QR (B), GD (C), WT (D) and AAA (E) DTG mice, and control littermates, as well as Kir6.1/ and Kir6.1+/+ littermates (F). *P < .05 versus
control by unpaired Student’s t tests in (B through F). G, Normalized averaged mean blood pressures of each genotype to the average value of
their STG control littermates illustrates the marked progression from hypotensive GD and GD-QR DTG to hypertensive Kir6.1/ and Kir6.1[AAA]
animals. H, Heart rates from each condition demonstrate no signiﬁcant difference by 1-way ANOVA. DTG indicates double-transgenic; GOF,
gain-of-function; LOF, loss of function; WT, wild-type.
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whether excess subunits might bind to other proteins (other
than regulatory SUR subunits), but the continuum of blood
pressure responses, correlated with the expected effects of
each genetic manipulation on physiological channel activity
(and see below) is a strong argument against the possibility
that level of Kir6 protein expression per se (or non-speciﬁc
interactions with other proteins) underlies the effects on
blood pressure.
Measurement of blood pressure in isoﬂurane-anesthetized
animals may be of concern for several reasons. There is
evidence that isoﬂurane can act as a KATP channel opener
22
which can provide a cardioprotective mechanism23 and might
preferentially activate KATP channels in GD and GD-QR DTG
mice. More generally, anesthesia might produce confounding
hemodynamic effects by altering baroreceptor function. We
therefore also assessed blood pressure plethysmographically
via tail cuff in conscious animals (Figure 4). These studies also
reveal 10 to 15 mm Hg decrease in systolic and diastolic
pressures in GD-QR DTG animals, and a corresponding increase
in Kir6.1/ mice, again without signiﬁcant change of heart
rate. The main concern for the use of plethysmography is that
the animals must be restrained, which can lead to artifactually
high pressure. Therefore, for these studies, the animals were
trained daily for 2 weeks prior to recording. Importantly, the
pressures in the control animals are consistent with measure-
ments obtained by telemetry in conscious mice.24,25
Kir6.1 GOF Enhanced KATP Currents in Freshly
Isolated Vascular Smooth Muscle Cells
To examine the effects of transgene expression on KATP
channel activity in VSM membranes, we measured currents
under whole-cell voltage-clamp in isolated single VSMCs from
mesenteric arteries of transgenic mice and control littermates
(Figure 5). Basal current in low (6 mmol/L) [K+] was insignif-
icant low (<1 pA/pF) in WT VSMCs (Figure 5A and 5C, control)
but increased substantially when external [K+] was elevated (to
140 mmol/L). Currents were further enhanced by the KATP
channel opener pinacidil, and almost completely inhibited by
glibenclamide, conﬁrming that the basal high [K+] current, as
well as the pinacidil-activated current was through KATP
channels. In GD DTG VSMCs, K+ currents were higher than
in WT VSMCs or VSMCs from STG littermates (Figure 5A and
5B) under all conditions, including basal, and signiﬁcantly so in
pinacidil. Conversely, there was no measurable KATP currents
observed in VSMCs from Kir6.1/ mice (Figure 5C and 5D).
Reduced Contractility but Normal Relaxation in
Isolated Blood Vessels From Kir6.1 GOF Mice
The enhanced basal and pinacidil-activated currents in GD
DTG myocytes are consistent with reduced excitability
underlying reduced contractility and hence reduced blood
pressures in the intact animal. To directly assess VSM
contractility, vessel diameter was assessed in isolated
mesenteric artery sections, in response to vasoactive agents
(Figure 6). Contraction in response to phenylephrine (PE) was
shifted 10-fold to higher [PE], in GD-QR DTG arteries
compared with WT control arteries (Figure 6A and 6B) and an
even greater relative shift was observed in the presence of the
KATP channel opener-pinacidil (Figure 6B). Conversely, in the
presence of glibenclamide, there was no statistical difference
in response between the 2 genotypes (Figure 6B). The KATP
speciﬁcity of this differential contractility is highlighted by the
ﬁnding that following constriction by high [PE], subsequent
KATP-independent relaxation in response to sodium nitroprus-
side was not different between the 2 genotypes.
Discussion
Kir6.1 Versus Kir6.2 in Native KATP Channel
Complexes
Two genes, KCNJ8 (Kir6.1) and KCNJ11 (Kir6.2), encode KATP
pore-forming subunits,26,27 while 2 SUR genes, ABCC8 (SUR1)
and ABCC9 (SUR2), generate regulatory subunits28,29 of KATP
channels. Kir6.1 and Kir6.2 confer distinct biochemical and
biophysical properties on the octameric channel complex, with
Kir6.1 channels exhibiting a marked requirement for Mg-nucle-
otide activation (Figure 1B) and being of lower conductance.5
While Kir6.2 is an obligatory subunit in skeletal and cardiac
muscle KATP channels, and prominent in pancreatic and
neuronal KATP channels, Kir6.1 is generally absent from these
tissues but is widely expressed throughout the vasculature.30
Accordingly, LOF mutations in Kir6.2 result in hypoglycemia
Figure 4. Kir6.1 GOF results in hypotension in conscious mice,
whereas Kir6.1 LOF results in hypertensive phenotype (A) Averaged
systolic, diastolic, and mean blood pressures from GD-QR DTG
(n=10), Kir6.1/ mice (n=5), and control mice (n=9). B, Averaged
heart rates demonstrate no signiﬁcant difference between the 3
groups. *P < .05 versus control by one-way ANOVA followed by
post-hoc Tukey’s test. DTG indicates double-transgenic; GOF,
gain-of-function; LOF, loss of function.
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and hyperinsulinemia, whereas Kir6.2 GOF mutations result in
pancreatic b-cell underactivity and neonatal diabetes.9,10 In
mice, deletion of Kir6.1 results in spontaneous coronary
vasospasm and a Prinzmetal angina–like phenotype,11 but the
consequences of overactivity of Kir6.1 in vivo are unknown.
Given the high sequence homology between Kir6.1 and Kir6.2,
we hypothesized that the GOF mutations in Kir6.1 that are
homologous to neonatal diabetes–causing Kir6.2 mutations
will cause pathology in mice and that these consequences
might parallel the relevant human diseases.
Certain disease-causing GOF Kir6.2 mutations (eg, Gly334
Asp19) are located in theATP binding site and alter ATP-sensitivity
directly, whereas others (eg, Gln52Arg20) are located outside the
binding pocket and alter ATP-sensitivity indirectly, by altering
intrinsic gating of the channel. We show that when engineered at
homologous residues in Kir6.1 (Gly343Asp and Gln53Arg)
(Figure 1A), each of the equivalent mutations cause loss of ATP
inhibition (Figure 1B and 1C) and increased channel activity in
the intact cell (Figure 1D). These data conﬁrm the structure–
function correlation between Kir6.1 and Kir6.2 and establish that
ATP inhibition is similarly sensitive to speciﬁc mutations in the
ATP-binding site and gating regions, thereby providing the critical
rationale to engineer Kir6.1 GOF in vivo.
Kir6.1 in Vascular Smooth Muscle KATP
Kir6.1 expression has been reported in numerous tissues,
prominently throughout the vasculature, although there is
evidence of variable biophysical and pharmacological proper-
ties in different VSM types, which likely reﬂect differential
expression of different subunits in vascular beds.2,31 Low-con-
ductance channels (unitary conductances from 20 to 50 pS),
which are inactive in isolated membrane patches and which
require nucleoside diphosphates (ADP, UDP, GDP) in the
presence of Mg2+ to open,31,32 are predominant and are likely
to reﬂect Kir6.1 subunits (Figure 1B).5,33
Figure 5. Kir6.1 GOF results in enhanced KATP channel currents in isolated arterial smooth muscle cells. A and C, Representative whole-cell
recordings of KATP currents in control (top) and GD DTG (A) or Kir6.1
/ (C) (bottom) VSMCs. VSMCs were sequentially exposed to low (6 mmol/L)
K+, high (140 mmol/L) K+, pinacidil, and glibenclamide. B and D, Summarized data show KATP current density in high K
+, pinacidil and
glibenclamide for GD DTG (B) or Kir6.1/ (D) and control littermate VSMCs. **P < .01 versus control at the same condition, by 2-way ANOVA
followed by Bonferroni’s posttests. DTG indicates double-transgenic; GOF, gain-of-function; VSMCs, vascular smooth muscle cells.
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KATP currents are reportedly normal in aortic smooth
muscle myocytes from Kir6.2/ mice.11,34 Here we show
that KATP currents are signiﬁcantly increased in VSMCs from
GD mice but absent in Kir6.1/ VSMCs (Figure 4C and 4D).
These data conﬁrm the essential requirement for Kir6.1
subunits in pinacidil- and glibenclamide-sensitive KATP cur-
rents in aortic smooth muscle. The current data also show
that expression of GD subunits increases basal KATP currents
more obviously than pinacidil-activated currents, reﬂecting
loss of ATP sensitivity in GD and suggesting that basal activity
Figure 6. Kir6.1 GOF results in decreased vascular reactivity of Kir6.1 GOF mouse mesenteric arteries. A, Representative recordings of vessel
diameter of (top) WT control and GD-QR DTG (bottom) mesenteric arteries in response to increasing phenylephrine (PE) concentrations. B,
Concentration-response of PE-induced vasoconstriction from experiments as in (A) (n=6 in each case) expressed as percent decrease in arterial
diameter after application of each concentration of PE (109 to 104 mmol/L) as indicated (top) and in the additional presence of glibenclamide
10 lmol/L (center) or pinacidil 100 lmol/L (bottom). C, Concentration-dependent vasodilatation of control and GD-QR DTG mesenteric arteries
in response to sodium nitroprusside (SNP) following constriction with 5 lmol/L PE. As indicated, percent relaxation shows no difference between
control (n=4) and GD-QR DTG (n=5) arterial diameter after application of PE and increasing concentration of SNP. Data are expressed as
meanSE in all cases. *P < .05, **P < .01 versus control at the same condition (2-way repeated-measures ANOVA followed by Bonferroni’s
posttests). DTG indicates double-transgenic; GOF, gain-of-function; WT, wild-type.
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of channels will be present in these VSMCs in vivo. It is also
noteworthy that glibenclamide inhibition of these currents is
less than the glibenclamide inhibition of WT channels, again
reﬂective of the loss of sulfonylurea sensitivity documented
for the open-state stabilizing Gln52Asp mutation in Kir6.2.20
Vascular KATP and Blood Pressure Control
KATP channels are presumed to be tonically active in many
vascular beds, and hence to play a role in establishing basal
vessel tone, based on glibenclamide-induced depolarization
and constriction, both in isolated arteries and in vivo.35
Pharmacological activation of KATP channels typically leads to
a lowering of intracellular Ca2+ levels, increase in arteriole
diameter, and decrease in vascular resistance,2 but the exact
target of such activators is not always clear. For instance,
there is controversy regarding the role of KATP channels in
smooth muscle versus channels in endothelium,36 and there
is signiﬁcant controversy regarding the action of KATP drugs
on mitochondrial versus surface membrane channels.30
Spontaneous coronary vasospasm and a Prinzmetal angina–
like phenotype that results from deletion of Kir6.111 or
SUR211,13 presumably reﬂect a normal role of channels
formed from these subunits somewhere in the vasculature,
potentially in smooth muscle, although restoration of WT
SUR2B expression in the latter case does not appear to
rescue the phenotype,36 implicating a smooth muscle extrin-
sic mechanism. Lower currents in glibenclamide compared
with high K+ alone in control VSMCs (Figure 4) indicates some
basal activity of these channels in isolated control VSMCs.
Gain of KATP channel activity is therefore predicted to cause a
relative hyperpolarization of the membrane potential, inhibi-
tion of L-type voltage-sensitive Ca2+-channels, Ca2+ entry,
accounting for the observed vasorelaxation and lowering of
blood pressure in ATP-insensitive GD DTG or GD-QR DTG
mice. Consistent with elevated basal KATP channel activity in
GD-QR GOF mesenteric arteries, we showed 10-fold shift in
the PE dependence of vessel contraction compared with WT
controls (Figure 6), which was absent in the presence of
glibenclamide and exacerbated in the presence of pinacidil
(Figure 6). Importantly, the blood pressure of WT/Cre-DTG
mice remained normal (Figure 3D), arguing that blood
pressure lowering in GD/Cre-DTG and GD-QR/Cre-DTG is a
result of reduced KATP channel ATP sensitivity and arguing
against a simple effect of overexpression of Kir6.1 subunits. In
addition, a recent study shows that overexpression of the KATP
channel Kir6.2 subunit does not affect endogenous SUR
subunit mRNA levels in mice,37 such that overexpression of
the Kir6 subunit per se will not alter SUR subunit levels, which
may limit the overall KATP channel density.
The data are entirely consistent with the introduced GOF
mutant channels causing primary hypotension. Although
previous studies did not report effects of total or partial loss
of Kir6.1 function on systemic blood pressures,11,12 the
current data, examining littermate controls, indicate that
knockout of Kir6.1 or expression of dominant-negative Kir6.1
[AAA] in VSM increase both systolic and diastolic pressures
(Figures 3 and 4), again consistent with basal KATP channel
activity being normally present in WT vessels. The direct
hyperpolarizing effects of ATP-insensitive Kir6.1 on VSM can
explain depressed vasoconstrictor responsiveness and con-
sequent hypotension. It might be expected that the
renin-angiotensin system or baroreceptor reﬂexes might
counter the hypotension. Little is known about the relative
efﬁcacy of the renin-angiotensin system in rodents versus
humans, and it remains to be seen whether there is in fact any
partial compensation through such mechanisms.
Genetic Alterations of Cardiovascular KATP in
Humans: Cantu Syndrome
Knockout animals have been generated for each of the 4 KATP
subunit genes.30 These animals have established that distinct
pairs form native channels in different tissues. Both SUR1 and
Kir6.2 knockouts reiterate a glucose-insensitive insulin secre-
tory phenotype due to loss of KATP in the pancreas.
7,38,39 GOF
Kir6.2 mutants in the pancreas cause severe neonatal diabetes
in mice10 and humans.9 Expression of GOF Kir6.2 subunits in
cardiac myocytes is well tolerated with minimal effect on heart
function,40,41 but again mimicking and predicting the benign
cardiac phenotype in neonatal diabetes.42 Thus, while SUR1
and Kir6.2 mutations clearly cause human disease through
alterations of pancreatic function, it has not been obvious what
the pathological consequences of Kir6.1 or SUR2mutations will
be in humans. Murine Kir6.1 and SUR2 knockouts reiterate a
phenotype mimicking human Prinzmetal angina,11,13 with
spontaneous coronary vasospasm leading to early death. Until
now, the only Kir6.1 transgenic animals that have been
generated express dominant-negative Kir6.1[AAA] subunit
under tamoxifen-Cre control and have been targeted only to
cardiac myocytes43 or to endothelium.12 The latter animals had
no overt phenotype and no early mortality, but there was an
elevated basal coronary perfusion pressure in isolated hearts,
suggesting a role for endothelium-expressed Kir6.1 in control of
vascular tone, potentially via elevated endothelin-1 release. Our
present demonstration that smooth muscle Kir6.1 LOF and
GOF, respectively, cause overt hypertension and hypotension
suggests that similar human pathologies might be expected
from Kir6.1 mutations. Intriguingly, the Kir6.1 and SUR2
genes are located on human chromosome 12p; chromosome
12p recombination has been shown to underlie autosomal
dominant hypertension,44 and postural hypotension is linked
to chromosome 12.45 Although our recent analysis of Kir6.1
and SUR2 genes in a cohort of such patients failed to reveal
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any associated variants,46 further investigation may be
warranted.
Strikingly, 2 recent studies showed conclusively that Cantu
syndrome results from SUR2 GOF mutations in humans.47,48
Cantu syndrome (MIM 239850) is a complex multiorgan
disease characterized by congenital hypertrichosis, edema,
macrocephaly, dysmorphic features, skeletal abnormalities,
and generalized osteopenia, as well as multiple additional
clinical features. Cardiovascular features include cardiac
hypertrophy, pulmonary hypertension, and pericardial effu-
sion. A signiﬁcant number of patients have had patent ductus
arteriosus requiring surgical closure, as well as bicuspid aortic
valve with and without stenosis. Marked edema involving the
lower extremities may develop over time, and in 1 patient,
lymphangiogram demonstrated dilated lymphatic vessels in
the legs with delayed lymphatic drainage.49 Previous studies
of Cantu syndrome patients provided no deﬁnitive explanation
of the underlying cause of the various features, and even now
the realization of SUR2 mutations as causal does not
immediately provide explanations for all features. The KATP
channel openers diazoxide and minoxidil have been used since
the 1960s to treat severe refractory hypertension, and
multiple side effects of these drugs include pronounced
hypertrichosis, pericardial effusions, and edema. Teratogenic
effects of minoxidil, including marked hypertrichosis, dysmor-
phic facial features, and low blood pressure, have been
reported in the offspring of a minoxidil-treated mother.50
Overt hypotension has not been reported in adult Cantu
syndrome patients, but edema, pericardial effusion, and
patent ductus arteriosus may all point to excessive vascular
relaxation. After birth, the abrupt increase in oxygen tension
and falling prostaglandin E2 and I2 levels lead to inhibition of
voltage-gated K channels and contraction of smooth muscle
ﬁbers in the ductus, resulting in wall thickening and lumen
obliteration. Enhancement of KATP current in the vessel
smooth muscle presents an obvious potential explanation
for excessive patent ductus arteriosus in Cantu syndrome.
These new analyses of Cantu syndrome patients focused on
the SUR2 (ABCC9) gene and uncovered coding mutations in 25
of 31 patients, but this still leaves 6 of these patients
unaccounted for. Given our ﬁndings, GOF mutations in Kir6.1
remain possible candidate causes. It should be pointed out
that several recent studies have reported a mutation,
Ser422Lys, in the Kir6.1 protein to be associated with the
“J-wave” phenomenon, characterized by abnormalities in the
J-point of the ECG.14,16 As part of the original study,14 we failed
to detect any alteration in the properties of Ser422Lys variant
Kir6.1/SUR2A currents in recombinant cells (J.C. Koster, PhD,
and C.G. Nichols, PhD, unpublished data), but the later studies
have reported enhanced channel activity for the Ser422Lys
variant, arguing that GOD in Kir6.1 channel activity is
underlying the ERS and hence atrial ﬁbrillation (AF). How this
occurs will require further examination, and the animals that
we have generated in the present study may be useful in this
regard. The results of the present study speciﬁcally illuminate
the role of Kir6.1 GOF in VSM, but with appropriate crosses,
these animals may also be used to test the role of Kir6.1 in
endothelium, as well as cardiac muscle and other tissues.
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